ALL Hub

New publication 📝 Results from the EWALL-INO trial published in the Journal of Clinical Oncology demonstrate efficacy of inotuzumab ozogamicin plus low-intensity chemotherapy in older patients with newly diagnosed CD22+ Ph− B-ALL. Learn more: https://loom.ly/EO3S4NQ #ALL #leusm #MedNews #MedEd

New publication 📝 Results from a retrospective analysis published in Hemasphere identified several factors associated with long-term survival in patients with ALL who were alive and disease-free 2 years after allo-HSCT. See: https://loom.ly/KF5Prrc #leusm #MedNews #MedEd

🚨 NEWS 🚨 @US_FDA grants marketing approval for obecabtagene autoleucel for the treatment of adult patients with relapsed/refractory B-ALL. This approval was based on results from the phase Ib/II FELIX study. Read more 👉 https://loom.ly/NpLOcuo #allsm #leusm #MedNews

A new study published in HemaSphere found that anti-CD19 CAR T-cells with shRNA IL-6 gene silencing element may improve the safety profile without compromising efficacy in patients with R/R B-ALL📝 More news: lymphoblastic-hub.com #ALLsm #leusm #MedNews #MedEd

New publication 📝 Results from a post hoc analysis of two phase I/II trials published in HemaSphere show that anti-CD19 CAR T-cells with shRNA IL-6 gene silencing may improve the safety profile in patients with R/R B-cell #ALL See: https://loom.ly/fg000pQ #ALLsm #leusm #MedNews #MedEd

Longitudinal follow-up results of phase II trial evaluating the impact of adding venetoclax to hyper-CVAD-nelarabine-pegAsp in adults with untreated T-ALL/LBL was published in Leukemia 📝 More news: lymphoblastic-hub.com #ALLsm #leusm #MedNews #MedEd

📝 Longitudinal follow-up results of phase II trial published in Leukemia showed the PFS benefit of adding venetoclax to hyper-CVAD-nelarabine-pegAsp in adult patients with untreated T-ALL/LBL. See: https://loom.ly/U6wJmk8 #ALLsm #leusm #MedNews #MedEd

🚨 NEWS 🚨 The @US_FDA expands oral methotrexate approval to include the treatment of pediatric patients with acute lymphoblastic leukemia. Read more here 👉 https://loom.ly/ECfdwnU #ALLsm #leusm #MedNews #MedEd

📝 Comparison of ZUMA-3 with historical trials published in Leukemia & Lymphoma found that brexu-cel improved OS vs SoC, including blinatumomab, inotuzumab, and chemotherapy, supporting brexu-cel for the treatment of patients aged ≥26 years with R/R B-ALL. More news: https://loom.ly/_2hHGdg #ALLsm #leusm #MedNews #MedEd

New publication 📝 Comparison of outcomes of patients in ZUMA-3 and historical trials published in Leukemia & Lymphoma showed clinical benefit of brexu-cel compared with SoC in patients aged ≥26 years with R/R B-ALL. See: https://loom.ly/vUVSAiM #ALLsm #leusm #MedNews #MedEd